TITLE

Authors' reply

AUTHOR(S)
Jover, R.; Castells, A.; Llor, X.; Andreu, M.
PUB. DATE
December 2006
SOURCE
Gut;Dec2006, Vol. 55 Issue 12, p1819
SOURCE TYPE
Academic Journal
DOC. TYPE
Letter
ABSTRACT
A response by R. Jover, A. Castells, X. Llor, and M. Andreu to a letter to the editor about their article on the lack of efficacy for 5-fluorouracil in patient with mismatch repair deficient tumor in the previous issue is presented.
ACCESSION #
23512284

 

Related Articles

  • Grouping of molecularly targeted anti-cancer agents based on cost-effectiveness analysis. Tirelli, U.; Berretta, M.; Bearz, A.; Carbone, A. // European Review for Medical & Pharmacological Sciences;2011, Vol. 15 Issue 11, p1355 

    A letter to the editor about the cost-effectiveness of molecularly targeted anti-cancer treatments is presented.

  • Treatment of Acute Hepatitis C with Interferon Alfa-2b. Seligman, Hilary K.; Fox, Rena K. // New England Journal of Medicine;4/4/2002, Vol. 346 Issue 14, p1091 

    A letter to the editor is presented in response to a study on the treatment of acute hepatitis C virus (HCV) infection with interferon alfa-2b by researcher Elmar Jaeckel and colleagues in the November 15, 2001 issue.

  • Drug-Eluting Coronary Stents. Windecker, Stephan; J�ni, Peter; Meier, Bernhard // New England Journal of Medicine;12/1/2005, Vol. 353 Issue 22, p2404 

    A response by Stephan Windecker and colleagues to several letters to the editor about their article "Sirolimus-Eluting and Paclitaxel-Eluting Stents for Coronary Revascularization," in the August 18, 2005 issue is presented.

  • RESPONSE. Hsin-Chia Hung; Joshipura, Kaumudi; Willett, Walter // JNCI: Journal of the National Cancer Institute;4/20/2005, Vol. 97 Issue 8, p608 

    Presents a letter to the editor regarding the possibility that fruits and vegetables contain anticancer properties.

  • Eliminating Cytotoxic Background Contamination.  // Journal of Pharmacy Practice & Research;2009, Vol. 39 Issue 3, p247 

    A letter to the editor is presented regarding cytotoxic contamination.

  • Crystal structure of ABT-737 complexed with Bcl-xL: implications for selectivity of antagonists of the Bcl-2 family. Lee, E. F.; Czabotar, P. E.; Smith, B. J.; Deshayes, K.; Zobel, K.; Colman, P. M.; Fairlie, W. D. // Cell Death & Differentiation;Sep2007, Vol. 14 Issue 9, p1711 

    A letter to the editor is presented about the crystal structure of the antitumor agent ABT-737.

  • Cell cycle-dependent cytotoxic and cytostatic effects of bortezomib on colon carcinoma cells. Coquelle, A; Mouhamad, S; Pequignot, M O; Braun, T; Carvalho, G; Vivet, S; Métivier, D; Castedo, M; Kroemer, G // Cell Death & Differentiation;May2006, Vol. 13 Issue 5, p873 

    A letter to the editor is presented commenting on the cell cycle-dependent cytostatic and cytotoxic effects on colon carcinoma cells of bortezomib.

  • Combination of imatinib with rapamycin or RAD001 acts synergistically only in Bcr-Abl-positive cells with moderate resistance to imatinib. Dengler, J.; von Bubnoff, N.; Decker, T.; Peschel, C.; Duyster, J. // Leukemia (08876924);Oct2005, Vol. 19 Issue 10, p1835 

    Presents a letter to the editor in response to the article "Combination of Imatinib With Rapamycin or RAD001 Acts Synergistically Only in Bcr-Abl-Positive Cells With Moderate Resistance to Imatinib," previously published in the journal "Leukemia."

  • The Genasense 'learning curve'. Stein, C. A. // Nature Biotechnology;Sep2007, Vol. 25 Issue 9, p972 

    A letter to the editor is presented in response to the article "Antisense—down but not out" which was published in the May 2007 issue.

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sign out of this library

Other Topics